Pelthos Therapeutics (PTHS) vs Genenta Science S.p.A. (SAEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Pelthos Therapeutics is the larger company by market cap ($25.1 million vs $24.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PTHS | SAEN |
|---|---|---|
| Share price | $6.38 | $0.5074 |
| Market cap | $25.08M | $24.47M |
| 1-day change | -8.73% | -9.39% |
| YTD return | -79.42% | — |
| 1-year return | -74.88% | — |
| EPS (TTM) | $-23.86 | $-0.37 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $16.80M | — |
| Net income (latest FY) | $-43.32M | — |
| Gross margin | 76.25% | — |
| Operating margin | -193.09% | — |
| Net margin | -257.93% | — |
| 52-week high | $31.62 | $2.58 |
| 52-week low | $6.02 | $0.50 |
| Distance from 52-week high | -79.82% | -80.33% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +732.92% | — |
| Average volume | 54.38K | 85.01K |
| Shares outstanding | 3.93M | 48.22M |
| Employees | 92 | 9 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Pelthos Therapeutics
PTHS stock →Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 92 employees
About Genenta Science S.p.A.
SAEN stock →Genenta Science S.p.A. operates as a strategic consolidator that focuses on acquiring ownership of privately held companies operating in Italian national-security-regulated sectors.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 9 employees
PTHS vs SAEN FAQ
Which is bigger, Pelthos Therapeutics or Genenta Science S.p.A.?
Pelthos Therapeutics (PTHS) is larger, with a market capitalization of $25.08M compared with $24.47M for Genenta Science S.p.A. (SAEN).
Are Pelthos Therapeutics and Genenta Science S.p.A. in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.